The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
the difficulty borrow shares is probably just down to the fact people have shorted uk and bought nasdq and it takes a few days to convert back.
It is the same application what makes you think an additional fee is required? Very unlikely the FDA would revisit their thoughts on a fee waiver!
I doubt the placing will be to existing shareholders rather an accelerated book build or strategic investor.
Dr Sandy aka the artist formerly known as Petch! Why do you bother? I am struggling to see why going onto a discussion board of a share you don't own is an exciting or rewarding way of spending your time. It is really weird and I can't really think what you get out of it.
There is definitely a tendency here to try and read positives where there is inference to glean and I'm sure I'm as guilty as most. As most LTH I've had the opportunity to average and trade a bit to the extent that I'm back with a position I feel a bit more comfortable with it (after dropping a few shares yesterday). Just a friendly reminder with Easter coming up about eggs and baskets!
There is definitely a tendency here to try and read positives where there is inference to glean and I'm sure I'm as guilty as most. As most LTH I've had the opportunity to average and trade a bit to the extent that I'm back with a position I feel a bit more comfortable with it (after dropping a few shares yesterday). Just a friendly reminder with Easter coming up about eggs and baskets!
Today feels like someone buying in that feels they wont be able to take part in the placing or that the placing will be smaller than expected.
Remember they have to repay hercules back something in a placing over £2million so I would expect that to be the max raise to keep the lights on.
AMP are selling because their lender told them to. The resignation of the Chairman probably has something to do with the fact his company will no longer be large shareholders. Pretty sure board will not want to be accused to rushing process again because AMP is so heavily indebted.
Also if you were really a doctor (which I really doubt you are having seemingly been born in 97) then you would know questions on liver toxicity are common on new drug applications particularly antiviral and antibiotics. Remember this application was fast tracked by a company trying to run on a low budget, with confidence of a positive result.
I think we are all trying to draw inferences here on incomplete and unknown information.
Richard Morgan who resigned today as chairman holds significant shareholdings and loan notes in AMP where he is CEO. AMP reducing their holding will be good for Motif in the long run (should approval be granted) so I see today's news as a positive.
This will not have a significant impact on motif. More of a reputational issue for them and putting a small antibiotic company out of business probably not a good look.
Paratek is waiting on a key patent extension!
Did anyone else notice that Hercules didn't require any further repayment of loan on a raise sub 2million. Suggests that the very short term funding might be in the ballpark?
I'm pretty sure they would be locked out from trading at the moment, they would have too much price sensitive information available.
How are you valuing it out of interest? What is your methodology? Have you got a CFA qualification? I think that a company like VRS is exceptionally difficult to value. However it has a separate income stream from the profitable silicon carbide business which will help protect against cash calls. Haydale and AGM look like they have made very little progress and are in a dire state financially. Graphene companies were always going to be a last man standing play as the stronger companies identify themselves over time. I think you have simply had a look at other companies and thought VRS is overvalued in comparison. There is nothing in your posts to suggest a modicum of serious, rigorous, disciplined research.
If you don't understand why amphion is terrible think of it this way. How much are amphions motif shares worth currently vs their debt. Now contrast that with how much it would cost to buy those shares at the current motif market cap.
Their debt is super opaque and there is very little information on the convertible loan notes owned by directors.
My guess is whoever has shorted motif will have bought some amphion for a levered hedge against a motif takeover.
You might well be right however at this valuation I think there is a risk of a smaller private/institutional placement for short term working capital where you miss out on the chance to get back in.
Have Government, Charities, Welcome Trust and others who have publicly stated their desire to help develop new antibiotics to address the chronic market failure in this area offered any support?